{"transactions":[{"id":4634135,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":16141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":144521,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16141},"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":4634134,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16141,"price":26.9341,"value":434743.3081,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":4634133,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":16141,"price":10.42,"value":168189.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16141,"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":3520894,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-08T20:20:35.000Z","date":"2026-09-04","kind":"sale","planned":true,"acquired":false,"shares":9705,"price":26.2238,"value":254501.979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000036","document":"form4-09082026_080930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000036/form4-09082026_080930.xml","form_type":"4"}},{"id":4497,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":59,"price":25.78,"value":1521.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."}],"balance_after":9705,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4496,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":5130,"price":26.0133,"value":133448.229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive."}],"balance_after":9764,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4495,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":625,"price":27.1211,"value":16950.6875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive."}],"balance_after":14894,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4494,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":4481,"price":26.376,"value":118190.856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":15519,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":2315,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2314,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":16141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":160662,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16141},"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2313,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2312,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":16141,"price":26.3622,"value":425512.2702,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2311,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":16141,"price":10.42,"value":168189.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16141,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":687113,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":16142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":176803,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16142},"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":687112,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":16142,"price":27.6063,"value":445620.8946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":687111,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":16142,"price":10.42,"value":168199.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16142,"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":718673,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":14609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":192945,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":14609},"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718672,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":30.3369,"value":36404.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.24 to $30.42 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718671,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":13409,"price":29.865,"value":400459.785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.24 to $30.23 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":1200,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718670,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":14609,"price":10.42,"value":152225.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":14609,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":752358,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":14853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":207554,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":14853},"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752357,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":26.3576,"value":42172.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752356,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":13253,"price":25.5746,"value":338940.1738,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":1600,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752355,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":14853,"price":10.42,"value":154768.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":14853,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":775436,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":222407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":775435,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":26.2236,"value":393354.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.44 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":775434,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":10.42,"value":156300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":820383,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":237407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":820382,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":31.0667,"value":9320.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.80 to $31.22 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":820381,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":3348,"price":30.0585,"value":100635.858,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.77 to $30.50 per share, inclusive."}],"balance_after":300,"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":820380,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":11352,"price":29.2414,"value":331948.3728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.77 to $29.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":3648,"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":820379,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":10.42,"value":156300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":832593,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T22:50:07.000Z","date":"2026-03-20","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":252407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000017","document":"form4-03202026_100302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000017/form4-03202026_100302.xml","form_type":"4"}},{"id":832592,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-20T22:50:07.000Z","date":"2026-03-20","kind":"sale","planned":true,"acquired":false,"shares":5044,"price":50.0186,"value":252293.8184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.79 to $50.52 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000017","document":"form4-03202026_100302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000017/form4-03202026_100302.xml","form_type":"4"}},{"id":832591,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-20T22:50:07.000Z","date":"2026-03-20","kind":"sale","planned":true,"acquired":false,"shares":3795,"price":49.3198,"value":187168.641,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.78 to $49.77 per share, inclusive."}],"balance_after":5044,"source":{"system":"sec-edgar","filing":"0002050172-26-000017","document":"form4-03202026_100302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000017/form4-03202026_100302.xml","form_type":"4"}},{"id":832590,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-20T22:50:07.000Z","date":"2026-03-20","kind":"sale","planned":true,"acquired":false,"shares":6161,"price":48.2027,"value":296976.8347,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.77 to $48.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":8839,"source":{"system":"sec-edgar","filing":"0002050172-26-000017","document":"form4-03202026_100302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000017/form4-03202026_100302.xml","form_type":"4"}},{"id":832589,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-20T22:50:07.000Z","date":"2026-03-20","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":10.42,"value":156300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0002050172-26-000017","document":"form4-03202026_100302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000017/form4-03202026_100302.xml","form_type":"4"}},{"id":846623,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T20:51:12.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":267407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0002050172-26-000015","document":"form4-03122026_080308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000015/form4-03122026_080308.xml","form_type":"4"}},{"id":846622,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-12T20:51:12.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":348,"price":51.015,"value":17753.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.09 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000015","document":"form4-03122026_080308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000015/form4-03122026_080308.xml","form_type":"4"}},{"id":846621,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-12T20:51:12.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":29652,"price":50.4454,"value":1495807.0008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":348,"source":{"system":"sec-edgar","filing":"0002050172-26-000015","document":"form4-03122026_080308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000015/form4-03122026_080308.xml","form_type":"4"}},{"id":846620,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-03-12T20:51:12.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":10.42,"value":312600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0002050172-26-000015","document":"form4-03122026_080308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000015/form4-03122026_080308.xml","form_type":"4"}},{"id":868977,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T21:23:12.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":24000,"derivative":{"underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0002050172-26-000013","document":"form4-03032026_090308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000013/form4-03032026_090308.xml","form_type":"4"}},{"id":868976,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:23:12.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":45.61,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0002050172-26-000013","document":"form4-03032026_090308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000013/form4-03032026_090308.xml","form_type":"4"}},{"id":919738,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":297407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":919737,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":47.23,"value":4723.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":919736,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":5936,"price":46.3732,"value":275271.3152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.20 to $47.17 per share, inclusive."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":919735,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":8364,"price":45.8891,"value":383816.4324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.20 to $46.19 per share, inclusive."}],"balance_after":6036,"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":919734,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":600,"price":44.205,"value":26523.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.29 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":14400,"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":919733,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-02-04T21:25:47.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":10.42,"value":156300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0002050172-26-000009","document":"form4-02042026_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000009/form4-02042026_090238.xml","form_type":"4"}},{"id":942470,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:51:26.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":false,"shares":25156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":312407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":25156},"source":{"system":"sec-edgar","filing":"0002050172-26-000006","document":"form4-01092026_090123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000006/form4-01092026_090123.xml","form_type":"4"}},{"id":942469,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-09T21:51:26.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":25156,"price":40.2011,"value":1011298.8716,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000006","document":"form4-01092026_090123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000006/form4-01092026_090123.xml","form_type":"4"}},{"id":942468,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-09T21:51:26.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":true,"shares":25156,"price":10.42,"value":262125.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":25156,"source":{"system":"sec-edgar","filing":"0002050172-26-000006","document":"form4-01092026_090123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000006/form4-01092026_090123.xml","form_type":"4"}},{"id":947383,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":false,"shares":412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":337563,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":412},"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":947382,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":4432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":337975,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":4432},"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":947381,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":412,"price":40,"value":16480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":947380,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":true,"shares":412,"price":10.42,"value":4293.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":412,"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":947379,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":4432,"price":40.4304,"value":179187.5328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.965 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":947378,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-01-06T21:31:52.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":4432,"price":10.42,"value":46181.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":4432,"source":{"system":"sec-edgar","filing":"0002050172-26-000003","document":"form4-01062026_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000003/form4-01062026_090146.xml","form_type":"4"}},{"id":956682,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T21:22:36.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":342407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0002050172-25-000007","document":"form4-12312025_091232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017225000007/form4-12312025_091232.xml","form_type":"4"}},{"id":956681,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2025-12-31T21:22:36.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":17200,"price":40.9262,"value":703930.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.51 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-25-000007","document":"form4-12312025_091232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017225000007/form4-12312025_091232.xml","form_type":"4"}},{"id":956680,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2025-12-31T21:22:36.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":27800,"price":40.339,"value":1121424.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.71 to $40.705 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":17200,"source":{"system":"sec-edgar","filing":"0002050172-25-000007","document":"form4-12312025_091232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017225000007/form4-12312025_091232.xml","form_type":"4"}},{"id":956679,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2025-12-31T21:22:36.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":45000,"price":10.42,"value":468900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0002050172-25-000007","document":"form4-12312025_091232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017225000007/form4-12312025_091232.xml","form_type":"4"}},{"id":1033235,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2025-09-24T20:24:14.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0002050172-25-000004","document":"form4-09242025_080911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017225000004/form4-09242025_080911.xml","form_type":"4"}}]}